The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

and human epidermal growth factor receptor 2 (HER2/neu)—that targeted medications act upon to reduce tumor growth. Even when initial treatment leads to remission, the chance of triple-negative ...

The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins ... breast cancer is similar to that of HER2-negative breast cancer, but it usually also includes ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.

These data need to be interpreted with caution, however, as approximately 20% of ER-negative patients (8% of the total population) included in the pooled studies had HER2-overexpressing tumors and ...

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.